Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.
Employees: 51-200
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
Mentions in press and media 3
| Date | Title | Description |
| 21.08.2024 | Glenmark and SalioGen: A New Era in Ophthalmic Treatments | In the bustling world of pharmaceuticals and biotechnology, two companies are making waves in the ophthalmic sector. Glenmark Therapeutics Inc. and SalioGen Therapeutics are not just players; they are pioneers. Their recent announcements re... |
| 19.08.2024 | SalioGen Therapeutics Appoints Kali Stasi, M.D., Ph.D. as Chief Medical Officer | -Dr. Stasi brings to SalioGen 30 years of experience in ophthalmology and genetic medicine- LEXINGTON, Mass., Aug. 19, 2024 /PRNewswire/ -- SalioGen Therapeutics, a biotechnology company developing next-generation genetic medicines based on... |
| 05.02.2024 | Adverum Biotechnologies Announces $127.5 Million Private Placement Financing | - |